Lardy N M, van der Horst A R, ten Berge I J, Surachno S, Wilmink J M, de Waal L P
Department of HLA Diagnostics, Central Laboratory of the Netherlands Red Cross-Blood Transfusion Service, Amsterdam.
Transplantation. 1997 Aug 27;64(4):612-6. doi: 10.1097/00007890-199708270-00012.
The aim of the present study was to analyze the effect of HLA-DRB1* mismatches on graft function and graft survival in 92 patients who received serologically HLA-DR split antigen-matched cadaveric renal transplants.
The polymorphic second exon of the HLA-DRB1 alleles was typed using the sequence-specific oligonucleotides technique.
The results show that in 26 of the 92 analyzed combinations, one or more HLA-DRB1* mismatches were found (28%). The analysis of the occurrence of treatable rejection episodes during the first 3 months after transplantation demonstrated a significantly higher incidence of rejection episodes in the HLA-DRB1*-mismatched group: 18 of 26 (69%) in the HLA-DRB1*-mismatched group against 23 of 66 (35%) in the HLA-DRB1*-matched group (P(uncorr)=0.0033). However, no effect of HLA-DRB1* mismatches on graft survival was found, although in general graft survival in the whole patient group was negatively influenced by the occurrence of rejection episodes during the first 3 months after transplantation (P(uncorr)=0.0008). In contrast, in the HLA-DR4-matched donor-recipient combinations (n=28), the effect of mismatching for the HLA-DRB1*04 alleles seemed to have a pronounced effect not only on the occurrence of rejection episodes but also in the form of diminished graft survival.
Thus, this study indicates that the existence of HLA-DRB1* allele mismatches in renal transplant recipients, matched for the serologically defined HLA-DR split antigens, is not harmful for the transplant. The exception is the HLA-DRB1*04 mismatch, which seems to be deleterious for the grafted organ.
本研究旨在分析92例接受血清学HLA-DR拆分抗原匹配的尸体肾移植患者中,HLA-DRB1*错配对接种功能和移植物存活的影响。
采用序列特异性寡核苷酸技术对HLA-DRB1等位基因的多态性第二外显子进行分型。
结果显示,在92个分析组合中的26个中,发现了一个或多个HLA-DRB1错配(28%)。对移植后前3个月内可治疗排斥反应发作情况的分析表明,HLA-DRB1错配组的排斥反应发作发生率显著更高:HLA-DRB1错配组26例中有18例(69%),而HLA-DRB1匹配组66例中有23例(35%)(P(未校正)=0.0033)。然而,未发现HLA-DRB1错配对移植物存活有影响,尽管总体而言,整个患者组的移植物存活受到移植后前3个月内排斥反应发作的负面影响(P(未校正)=0.0008)。相比之下,在HLA-DR4匹配的供体-受体组合(n=28)中,HLA-DRB104等位基因错配的影响似乎不仅对排斥反应发作的发生有显著影响,而且以移植物存活降低的形式表现出来。
因此,本研究表明,在血清学定义的HLA-DR拆分抗原匹配的肾移植受者中,HLA-DRB1等位基因错配的存在对移植无害。例外情况是HLA-DRB104错配似乎对移植器官有害。